title: Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
abstract: BACKGROUND
  Postoperative 5-fluorouracil (5-FU)-based chemotherapy improves survival after resection of synchronous liver metastases from colorectal cancer (CRLM). We retrospectively assessed the efficacy of postoperative chemotherapy with a modern regimen containing of oxaliplatin or irinotecan after curative resection of synchronous CRLM.
  
  
  METHODS
  Seventy-two patients who received postoperative chemotherapy following curative resection of synchronous CRLM were analyzed. Patients were categorized into fluorouracil plus leucovorin (5-FU/LV, n=25), irinotecan-based regimen (FOLFIRI/IFL, n=21) and oxaliplatin-based regimen (FOLFOX, n=26) groups, according to the postoperative chemotherapy regimen. The clinicopathological parameters of patients were analyzed to evaluate clinical outcome.
  
  
  RESULTS
  Median relapse-free survival (RFS) was 14.4 months in the 5-FU/LV group vs. 20.8 months in the FOLFIRI/IFL group (p=0.032) and 18.8 months in the FOLFOX regimen (p=0.123). Median overall survival (OS) was >60 months in the FOLFOX and FOLFIRI/IFL groups vs. 38.5 months in the 5-FU/LV group (p=0.002 and p=0.019, respectively). In multivariate analysis, administrations of FOLFIRI/IFL or FOLFOX regimens were independent predictive factors for favorable RFS. Administration of the FOLFIRI/IFL regimen was the only independent predictive factor for favorable OS.
  
  
  CONCLUSIONS
  Postoperative FOLFIRI/IFL and FOLFOX chemotherapy lead to more favorable RFS than 5-FU/LV following curative resection of synchronous CRLM.
authors.affiliation: Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, 5 Fu-Hsing Street, Kwei-Shan, Tao-Yuan 333, Taiwan, ROC. a481124@adm.cgmh.org.tw
authors.forename: Hung-Chih
authors.initials: HC
authors.lastname: Hsu
authors.forename: Wen-Chi
authors.initials: WC
authors.lastname: Chou
authors.forename: Wen-Chi
authors.initials: WC
authors.lastname: Shen
authors.forename: Chiao-En
authors.initials: CE
authors.lastname: Wu
authors.forename: Jen-Shi
authors.initials: JS
authors.lastname: Chen
authors.forename: Chi-Ting
authors.initials: CT
authors.lastname: Liau
authors.forename: Yung-Chang
authors.initials: YC
authors.lastname: Lin
authors.forename: Tsai-Sheng
authors.initials: TS
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000473:pathology*; D003710:Demography; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011182:Postoperative Care; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002166:Camptothecin
keywords: 5-fluorouracil; FOLFIRI; FOLFOX; Postoperative chemotherapy; colorectal liver metastasis; irinotecan; leucovorin; oxaliplatin; synchronous metastasis